Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03039478
Other study ID # PolyDose
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 24, 2017
Est. completion date August 31, 2018

Study information

Verified date September 2018
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Xylitol and erythritol have become increasingly popular as sugar substitutes in the food industry. Both substances are freely available. While glucose ingestion stimulates satiation hormone secretion in the gut and slows down gastric emptying, artificial sweeteners such as aspartame, sucralose and acesulfame-K have no such effect. However, acute intake of 50g xylitol or 75g erythritol in 300mL tap water leads to a marked increase in the satiation hormones and induces a significant retardation in gastric emptying. The concentrations used to Show this effect were rather high (50g xylitol and 75g erythritol) and led to bloating and diarrhea in 60-70% of all subjects two hours after administration. The aim of the present study is to find an effective concentration of xylitol and erythritol still stimulating satiation hormone release without any gastrointestinal adverse events.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date August 31, 2018
Est. primary completion date August 31, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Healthy normal weight subjects with a body-mass index of 19.0-24.9

- Normal eating habits (no diets; no dietary changes; no special dietary habits, such as vegetarian/vegan)

- Age 18-40 years

- Stable body weight for at least three months

- Informed Consent as documented by signature

Exclusion Criteria:

- Pre-existing consumption of xylitol or erythritol on a regular basis (usage of xylitol or erythritol as sugar replacement; xylitol or erythritol containing toothpaste is allowed)

- Regular intake of medications (except for oral contraceptives)

- Evidence of relevant cardiovascular, pulmonary, renal, hepatic, pancreatic, gastrointestinal, metabolic, endocrinological, neurological, psychiatric or other diseases at screening

- Clinically relevant abnormalities in haematological laboratory parameters

- Food allergies, food intolerance

- Pregnancy

- Participation in another study with investigational drug within the 30 days preceding and during the present study.

Study Design


Related Conditions & MeSH terms

  • Physiological Satiation Mechanisms

Intervention

Dietary Supplement:
Xylitol 7g
Xylitol 7g in 300mL tap water
Erythritol 10g
Erythritol 10g in 300mL tap water
Xylitol 17g
Xylitol 17g in 300mL tap water
Xylitol 35g
Xylitol 35g in 300mL tap water
Erythritol 25g
Erythritol 25g in 300mL tap water
Erythritol 50g
Erythritol 50g in 300mL tap water

Locations

Country Name City State
Switzerland University Hospital Basel Basel

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute effect on cholecystokinin ( CCK) release effect on CCK release measured by a commercially available ELISA kit (enzyme-linked immunosorbent assay) changes from baseline to three hours after treatment
Secondary Acute effects on gastric emptying Acute effects on gastric emptying measured by 13C-sodium-acetate breath test changes from baseline to three hours after treatment
Secondary Acute effects on subjective feelings of hunger and satiety Acute effects on subjective feelings of hunger and satiety measured by visual analogue scales changes from baseline to three hours after treatment
See also
  Status Clinical Trial Phase
Completed NCT04027283 - Acute Effects of the Two Alternative Sweeteners D-allulose and Erythritol on Metabolism N/A